Dyne Therapeutics 40% Rally Faces Fund Selloff Questions
A dramatic 40% jump for Dyne Therapeutics has investors watching closely as a biotech-focused fund disclosed a sizabl...
Check which passive funds beat the market in 2024 retirement planning and what factors contributed to their outperformance.
28,482 articlesA dramatic 40% jump for Dyne Therapeutics has investors watching closely as a biotech-focused fund disclosed a sizabl...
South Korea’s Kospi surged about 8% as investors chased growth stocks amid a debt-fueled rally. A Samsung labor deal ...
Looking for a long-term growth plan? This article highlights three growth stocks to hold next for the next two decade...
As U.S. Treasury yields climb, the tax advantages of municipal bonds are under fresh scrutiny. High-income investors ...
A new Harvard Law study analyzes whether a safety-focused mission can survive investor pressure as Anthropic prepares...
The Nasdaq trades near flat as investors weigh a Middle East deal and a SpaceX IPO. Markets face a cautious open as e...
A hypothetical spacex stock $2.5 trillion valuation invites big questions about revenue, profitability, and risk. Thi...
A year into UVXY's latest cycle, a $10,000 stake has fallen far beyond typical market moves. The fund's mechanics hav...
SpaceX joined the Nasdaq-100 with high expectations, but the first day brought a meaningful pullback. This guide brea...
When a prominent investor trims a large stake, the market often swings. This piece breaks down what happened with Aca...
Regulators signal a softer approach while a Trump-linked venture secures $75 million from Justin Sun, fueling specula...
Signet Jewelers is not just selling rings anymore. A pivot to lab-grown diamonds is reshaping growth and margins. Thi...